Sumitovant Biopharma acquires remaining stake in Urovant Sciences
Clients Sumitomo Dainippon Pharma
Jones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash. Sumitovant previously owned 72% of the outstanding shares of Urovant common stock. The acquisition consideration represents an equity value for Urovant of $584 million and an enterprise value of $681 million. Upon closing, Urovant became a wholly owned subsidiary of Sumitovant and Urovant’s common stock ceased trading on the Nasdaq stock market.